Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Jazz Pharma Plc (JAZZ)

Jazz Pharma Plc (JAZZ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,305,616
  • Shares Outstanding, K 61,364
  • Annual Sales, $ 2,364 M
  • Annual Income, $ 238,620 K
  • 60-Month Beta 0.97
  • Price/Sales 3.49
  • Price/Cash Flow 8.09
  • Price/Book 2.03
Trade JAZZ with:

Options Overview Details

View History
  • Implied Volatility 35.85%
  • Historical Volatility 23.67%
  • IV Percentile 43%
  • IV Rank 34.74%
  • IV High 53.77% on 10/30/20
  • IV Low 26.31% on 06/16/21
  • Put/Call Vol Ratio 0.17
  • Today's Volume 307
  • Volume Avg (30-Day) 377
  • Put/Call OI Ratio 0.80
  • Today's Open Interest 2,135
  • Open Int (30-Day) 6,208

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate 2.46
  • Number of Estimates 5
  • High Estimate 3.00
  • Low Estimate 2.06
  • Prior Year 3.86
  • Growth Rate Est. (year over year) -36.27%

Price Performance

See More
Period Period Low Period High Performance
1-Month
127.80 +4.82%
on 09/21/21
138.64 -3.37%
on 09/24/21
+0.82 (+0.61%)
since 08/27/21
3-Month
127.80 +4.82%
on 09/21/21
186.22 -28.06%
on 07/12/21
-47.12 (-26.02%)
since 06/25/21
52-Week
127.80 +4.82%
on 09/21/21
189.00 -29.12%
on 06/15/21
-5.62 (-4.02%)
since 09/25/20

Most Recent Stories

More News
Axsome (AXSM) Begins Late-Stage Sleep Disorder Study on AXS-12

Axsome (AXSM) is developing AXS-12 as a potential treatment for narcolepsy. The company initiates enrollment in a phase III study evaluating AXS-12.

PFE : 43.57 (-0.84%)
JAZZ : 133.83 (-1.12%)
AXSM : 34.65 (+3.74%)
HRMY : 38.16 (+1.38%)
Jazz Pharmaceuticals Announces Xywav® (calcium, magnesium, potassium, and sodium oxybates) Investor Webcast on October 13, 2021

/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will host a webcast on at / to provide an update on Xywav (calcium, magnesium, potassium and sodium oxybates),...

JAZZ : 133.83 (-1.12%)
Are CBD Stocks Ready to Ride Again? (JAZZ, YCBD, NEPT, CVSI, MJNA, ALST)

NEPT : 0.6645 (+9.29%)
MJNA : 0.0261 (+0.38%)
CVSI : 0.2635 (+1.35%)
JAZZ : 133.83 (-1.12%)
GRPS : 0.0095 (+1.06%)
ALST : 0.0224 (-4.68%)
YCBD : 2.01 (-1.47%)
Jazz Pharmaceuticals to Participate in Upcoming September Investor Conferences

/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will participate in the following upcoming virtual investor conferences:

JAZZ : 133.83 (-1.12%)
Jazz (JAZZ) Down 14.1% Since Last Earnings Report: Can It Rebound?

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

JAZZ : 133.83 (-1.12%)
Jazz Pharmaceuticals Announces Health Canada Approval of Sunosi® (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea

COMTEX_392486368/2669/2021-08-31T08:01:22

JAZZ : 133.83 (-1.12%)
Biotech Veteran David Kideckel Joins the Board of PharmaDrug

Toronto, Ontario--(Newsfile Corp. - August 30, 2021) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("" or the ""), a specialty pharmaceutical company focused on the research, development and commercialization...

JAZZ : 133.83 (-1.12%)
PHRX.CN : 0.045 (unch)
LMLLF : 0.0310 (-11.43%)
Bio-Path (BPTH) to Begin Clinical Study on Leukemia Drug

Bio-Path Holdings' (BPTH) IND application for BP1002 receives clearance from the FDA. It is set to begin a phase I/Ib study for treating AML patients. The stock rises following the announcement.

RHHBY : 45.6100 (-0.87%)
BPTH : 5.28 (-0.38%)
JAZZ : 133.83 (-1.12%)
ABBV : 107.72 (+0.61%)
Delta 9 Appoints David Kideckel as Head of Strategy, Corporate Development & Capital Markets

DELTA 9 CANNABIS INC. (TSX: DN) (OTCQX: DLTNF) ("Delta 9" or the "Company"), is pleased to announce that it has appointed Dr. David Kideckel, PhD, MBA as Executive Vice President, Head of Strategy, Corporate...

JAZZ : 133.83 (-1.12%)
DN.TO : 0.4400 (+7.32%)
DLTNF : 0.3465 (+4.24%)
Pharma Stock Roundup: FDA Nod for SNY's Pompe Drug & New Use of MRK's Keytruda

FDA approves Sanofi's (SNY) Nexviazyme for late-onset Pompe disease and Merck's (MRK) Keytruda plus Lenvima for first-line kidney cancer.

SNY : 48.12 (+0.38%)
AZN : 58.72 (-2.70%)
NVS : 82.59 (-0.41%)
PFE : 43.57 (-0.84%)
MRK : 73.36 (-0.34%)
JAZZ : 133.83 (-1.12%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. Company's goal is to build a broad portfolio of products through a combination of internal development and...

See More

Key Turning Points

3rd Resistance Point 142.78
2nd Resistance Point 140.71
1st Resistance Point 138.03
Last Price 133.83
1st Support Level 133.28
2nd Support Level 131.21
3rd Support Level 128.53

See More

52-Week High 189.00
Fibonacci 61.8% 165.62
Fibonacci 50% 158.40
Fibonacci 38.2% 151.18
Last Price 133.83
52-Week Low 127.80

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar